Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton's tyrosine kinase

S. Krajčovičová, R. Jorda, D. Vanda, M. Soural, V. Kryštof

. 2021 ; 211 (-) : 113094. [pub] 20201209

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21019275

Grantová podpora
NV17-31834A MZ0 CEP - Centrální evidence projektů

Herein, we report an efficient synthetic approach towards trisubstituted imidazo [4,5-c]pyridines designed as inhibitors of Bruton's tyrosine kinase (BTK). Two alternative synthetic routes for the simple preparation of desired compounds with variable substitutions at the N1, C4, C6 positions were introduced with readily available building blocks. Further, the developed synthetic approach was feasible for isomeric compounds bearing imidazo [4,5-b]pyridine scaffolds. In contrast to expectations based on previous studies, the imidazo [4,5-c]pyridine inhibitor exhibited a significantly higher activity against BTK compared to its imidazo [4,5-b]pyridine isomer. An inherent SAR study in the series of imidazo [4,5-c]pyridine compounds revealed a remarkably high tolerance of C6 substitutions for both hydrophobic and hydrophilic substituents. Preliminary cellular experiments indicated selective BTK targeting in Burkitt lymphoma and mantle cell lymphoma cell lines. The inhibitors could thus serve as starting points for further development, eventually leading to BTK inhibitors that could be used after ibrutinib failure.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019275
003      
CZ-PrNML
005      
20210830100844.0
007      
ta
008      
210728s2021 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejmech.2020.113094 $2 doi
035    __
$a (PubMed)33340912
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Krajčovičová, Soňa $u Department of Organic Chemistry, Faculty of Science, Palacký University, 17. Listopadu 12, 77146, Olomouc, Czech Republic
245    10
$a 1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton's tyrosine kinase / $c S. Krajčovičová, R. Jorda, D. Vanda, M. Soural, V. Kryštof
520    9_
$a Herein, we report an efficient synthetic approach towards trisubstituted imidazo [4,5-c]pyridines designed as inhibitors of Bruton's tyrosine kinase (BTK). Two alternative synthetic routes for the simple preparation of desired compounds with variable substitutions at the N1, C4, C6 positions were introduced with readily available building blocks. Further, the developed synthetic approach was feasible for isomeric compounds bearing imidazo [4,5-b]pyridine scaffolds. In contrast to expectations based on previous studies, the imidazo [4,5-c]pyridine inhibitor exhibited a significantly higher activity against BTK compared to its imidazo [4,5-b]pyridine isomer. An inherent SAR study in the series of imidazo [4,5-c]pyridine compounds revealed a remarkably high tolerance of C6 substitutions for both hydrophobic and hydrophilic substituents. Preliminary cellular experiments indicated selective BTK targeting in Burkitt lymphoma and mantle cell lymphoma cell lines. The inhibitors could thus serve as starting points for further development, eventually leading to BTK inhibitors that could be used after ibrutinib failure.
650    _2
$a proteinkinasa BTK $x antagonisté a inhibitory $7 D000077329
650    _2
$a lidé $7 D006801
650    _2
$a nehodgkinský lymfom $x farmakoterapie $7 D008228
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a inhibitory proteinkinas $x farmakologie $x terapeutické užití $7 D047428
650    _2
$a pyridiny $x farmakologie $x terapeutické užití $7 D011725
650    _2
$a signální transdukce $7 D015398
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
655    _2
$a časopisecké články $7 D016428
700    1_
$a Jorda, Radek $u Laboratory of Growth Regulators, Palacký University & Institute of Experimental Botany, The Czech Academy of Sciences, Šlechtitelů 27, 78371, Olomouc, Czech Republic
700    1_
$a Vanda, David $u Department of Organic Chemistry, Faculty of Science, Palacký University, 17. Listopadu 12, 77146, Olomouc, Czech Republic
700    1_
$a Soural, Miroslav $u Department of Organic Chemistry, Faculty of Science, Palacký University, 17. Listopadu 12, 77146, Olomouc, Czech Republic; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 5, 77900, Olomouc, Czech Republic. Electronic address: miroslav.soural@upol.cz
700    1_
$a Kryštof, Vladimír $u Laboratory of Growth Regulators, Palacký University & Institute of Experimental Botany, The Czech Academy of Sciences, Šlechtitelů 27, 78371, Olomouc, Czech Republic; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 5, 77900, Olomouc, Czech Republic. Electronic address: vladimir.krystof@upol.cz
773    0_
$w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 211, č. - (2021), s. 113094
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33340912 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100844 $b ABA008
999    __
$a ok $b bmc $g 1690166 $s 1139721
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 211 $c - $d 113094 $e 20201209 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
GRA    __
$a NV17-31834A $p MZ0
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...